---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-005280"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-04-18T23:59:59+00:00"
generated_at: "2026-06-03T18:08:49.004660+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bio-Path completes second dose cohort in Phase 1/1b trial of BP1002 in AML

## Summary
- Second dose cohort (40 mg/m²) completed in dose escalation for refractory/relapsed AML patients, including venetoclax-resistant.
- Trial will pause for FDA data review; next planned dose is 60 mg/m² in monotherapy.
- BP1002 targets Bcl-2 at mRNA level, may overcome venetoclax resistance; preclinical data showed potent inhibition.
- Phase 1b combination with decitabine expected after monotherapy cohorts; enrollment rates described as good.

## SEC filing metadata
- accession: 0001558370-24-005280
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024005280/0001558370-24-005280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024005280/bpth-20240418x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-005280
- JSON: https://secwatch.observer/filing/0001558370-24-005280.json
- Plain text: https://secwatch.observer/filing/0001558370-24-005280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.